---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-24-000008"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:48:33.931561+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q4 sales down 6.7% YoY; Life Science segment declines 19.1%

## Summary
- Q4 net sales $681.2M, down 6.7% YoY; currency-neutral sales down 7.7%.
- Life Science segment sales $291.1M, down 19.1% YoY on broad-based weakness.
- Clinical Diagnostics segment sales $389.0M, up 5.3% YoY on diabetes and quality control demand.
- Net income $349.7M ($12.14 diluted EPS) vs $827.7M ($27.78) a year ago, impacted by Sartorius fair value changes.
- CEO cites ongoing biopharma weakness; expects gradual recovery in H2 2024.

## SEC filing metadata
- accession: 0000012208-24-000008
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/0000012208-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/bio-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-24-000008
- JSON: https://secwatch.observer/filing/0000012208-24-000008.json
- Plain text: https://secwatch.observer/filing/0000012208-24-000008.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the quarter ended December 31, 2023 results: revenue $681.2 million, net income $349.7 million, EPS $12.14 per share, on a diluted basis.
  - Period: the quarter ended December 31, 2023
  - Revenue: $681.2 million
  - Net income: $349.7 million
  - EPS: $12.14 per share, on a diluted basis
  - Result: reported results
  source text: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.7 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the fourth quarter of 2023 versus approximately $13.4 million in the year ago period. Excluding COVID-related sales, revenue decreased 6.0 percent on a currency-neutral basis. Life Science segment net sales for the fourth quarter were $291.1 million, a decline of 19.1 percent compared to the same period in 2022. On a currency-neutral basis, Life Science segment sales decreased by 19.9 percent compared to the same quarter in 2022. Excluding COVID-related sales, Lif
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/0000012208-24-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.